<DOC>
	<DOCNO>NCT01381471</DOCNO>
	<brief_summary>The specific aim study describe 1 year Advair dispense rate patient COPD , measure association Advair adherence healthcare utilization ( e.g . emergency room visit inpatient admission , etc. ) . To compare risk COPD exacerbation ( moderate severe ) 3-month follow-up period patient thqat adherent versus .</brief_summary>
	<brief_title>Fluticasone Propionate-salmeterol Combination Adherence Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>INCLUSION CRITERIA least one pharmacy claim Advair ( strength ; Diskus MDI ) index year ( July 1 , 2005 June 30 , 2006 ) . Continuous medical pharmacy eligibility 12 month PreIndex year 12 month Index year ( refer 24 month Observation Period ) , 3 month PostIndex period ( referred Outcome Period ) . At least one medical claim diagnosis ( either primary secondary ) COPD ( ICD9 code 490.xx , 491.xx , 492.xx , 496 ) , AND least 1 pharmacy claim Anticholinergic medication , occur the12 month preindex period . At least 40 year old index date . EXCLUSION CRITERIA medical claim ( ever ) primary secondary diagnosis cystic fibrosis ( ICD9 code 277.0x ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>